Prof. PeptideProf. Peptide

Bacopa Monnieri

Cognitive & Nootropic

Last reviewed: May 26, 2026

Also Known As: Brahmi, water hyssop, thyme-leaved gratiola, herb of grace, BM, bacosides

Supplement Class: Ayurvedic adaptogenic herb / cumulative nootropic (bacoside-standardized triterpenoid saponin extract)

Evidence Tier: Strong — Kongkeaw et al. 2014's meta-analysis of 9 RCTs; multiple independent 12-week RCTs (Stough et al. 2001, Roodenrys et al. 2002, Calabrese et al. 2008, Stough et al. 2008) consistently reporting chronic memory and anxiolytic effects, among the better-supported herbal nootropics in the Western literature reviewed.

Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

What is Bacopa monnieri?

Bacopa monnieri is a creeping aquatic herb native to South Asian wetlands and a cornerstone of Ayurvedic medicine, traditionally used for memory and cognitive support. Its active compounds, bacosides A and B (triterpenoid saponins), drive the modern nootropic case. Unlike most cognitive supplements that produce acute, same-day effects, Bacopa is reported to work through structural neural remodeling: dendritic branching, synaptic protein synthesis, acetylcholinesterase inhibition, and antioxidant neuroprotection. The cognitive benefits are reported as cumulative, building over 8–12 weeks of consistent use. It is one of the better-studied herbal nootropics in Western science — multiple independent 12-week RCTs (Stough, Roodenrys, Calabrese) and the Kongkeaw et al. 2014 meta-analysis consistently report improvements in delayed recall and information retention in healthy adults. It is discussed alongside cognitive peptides that work on a different timescale — acute focus and resilience from the peptides, chronic memory consolidation from Bacopa.

Reported benefits:

  • Improved delayed recall and memory consolidation (the most-replicated RCT finding)
  • Reduced rate of forgetting newly learned material (Roodenrys et al. 2002)
  • Anxiety and depression reduction in older adults (Calabrese et al. 2008)
  • Speed of information processing and rapid visual information processing (Stough trials)
  • Antioxidant neuroprotection in hippocampal neurons
  • Mild acetylcholinesterase inhibition (same mechanism class as donepezil, at lower magnitude)
  • Serotonergic modulation and cortisol response shaping under chronic stress

Common dose: 300 mg once daily of an extract standardized to 50–55% bacosides, the dose used in nearly all positive RCTs. Split dosing (150 mg twice daily with meals) is used for GI tolerability. Higher doses (600 mg/day) are tolerated but do not clearly accelerate the 8–12 week timeline.

Reported safety considerations: Thyroid medication interaction (Bacopa may modestly elevate T4 in animal models), cholinesterase-inhibitor drug interactions, and additive sedation with other CNS depressants. Data on pregnancy and breastfeeding is insufficient.

On this page
  1. 1.How does Bacopa monnieri work?
  2. 2.What does the evidence say Bacopa monnieri does?
  3. 3.How is Bacopa monnieri dosed?
  4. 4.How Bacopa monnieri is taken
  5. 5.What does Bacopa monnieri stack with?
  6. 6.Side effects and interactions
  7. 7.How should Bacopa monnieri be stored?
  8. 8.What isn't established about Bacopa monnieri
  9. 9.Product-quality considerations
  10. 10.Bacopa monnieri FAQ
  11. 11.References
  12. 12.Published Studies

How does Bacopa monnieri work?

Bacopa is reported to work through several parallel mechanisms, most notably bacoside-driven dendritic branching and synaptic remodeling in hippocampal neurons. This mechanism is structural rather than receptor-level, consistent with cognitive effects building over weeks rather than appearing acutely. Acetylcholinesterase inhibition and serotonergic modulation are discussed as additional layered mechanisms for memory and mood.

  1. Bacoside-driven synaptic remodeling. Bacosides A and B (the dominant active triterpenoid saponins) are reported to enhance kinase activity, neuronal protein synthesis, and dendritic branching in hippocampal neurons — the structural remodeling proposed to underlie Bacopa's chronic memory effect, and the reason a single dose produces no measurable acute effect.
  2. Acetylcholinesterase inhibition. Bacopa is reported to inhibit acetylcholinesterase, the enzyme that breaks down acetylcholine, raising cholinergic tone in cortex and hippocampus — the same mechanism class as donepezil and rivastigmine (Alzheimer's medications), at a much milder magnitude. This arm is discussed as contributing to attention and short-term memory effects.
  3. Antioxidant neuroprotection. Bacosides are reported as free-radical scavengers in brain tissue that upregulate endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase), protecting hippocampal neurons from oxidative damage — a mechanism implicated in cognitive aging and neurodegeneration.
  4. Serotonergic and HPA-axis modulation. Bacopa is reported to enhance serotonergic neurotransmission and modulate cortisol response under stress — the proposed mechanistic basis for the anxiolytic effects documented in Calabrese et al. 2008 and other chronic-use trials.
  5. Cerebral blood flow. Animal and limited human data suggest Bacopa may increase cerebral blood flow, potentially via nitric-oxide-mediated vasodilation. Clinical relevance is unclear, though this is a recurring finding in the preclinical literature.

What does the evidence say Bacopa monnieri does?

Bacopa has one of the deeper Western RCT bases of any traditional herbal nootropic. The strongest evidence is for chronic memory consolidation and information retention in healthy adults; secondary evidence covers anxiety reduction and processing speed. Acute effects are essentially absent in the trial data reviewed.

  1. Memory consolidation and information retention (Strong). Multiple 12-week RCTs (Stough et al. 2001, Roodenrys et al. 2002, Calabrese et al. 2008, Stough et al. 2008) consistently report Bacopa improves delayed recall and reduces the rate of forgetting newly learned material. The Kongkeaw et al. 2014 meta-analysis (9 RCTs, n=437) confirms the effect across pooled data. The cognitive gain is specifically retention-oriented; working memory and acute attention effects are reported as smaller.
  2. Processing speed and attention (Moderate). The Stough group's chronic Bacopa trials report significant improvements in speed of information processing and rapid visual information processing after 90 days, with a consistent directional signal across independent trials.
  3. Anxiety and mood (Moderate). Calabrese et al. 2008 reports significant reductions in anxiety and depression scale scores in older adults at 12 weeks. Stough et al. 2008 reports reductions in state anxiety. The anxiolytic effect is chronic and gradual, unlike acute anxiolytics, but documented in the RCT literature reviewed.
  4. ADHD and pediatric cognition (Emerging). Indian RCTs in children with ADHD suggest cognitive improvements, but the evidence base is limited and has not been replicated outside India.
  5. Neuroprotection in aging (Mechanism-based). Preclinical evidence supports antioxidant neuroprotection and reduced beta-amyloid burden in animal models. Human trials in MCI and Alzheimer's disease are limited relative to the broader cognitive-enhancement case in healthy adults.

How is Bacopa monnieri dosed?

Bacopa dosing in the trial literature is built around standardized extracts rather than raw powder, which is more variable. The published RCT dose is 300 mg/day of an extract standardized to 50–55% bacosides; a few trials use up to 600 mg/day. Higher doses do not appear to accelerate the timeline — the 8–12 week onset is reported as structural and largely dose-insensitive within the studied range.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

  1. Standard daily dose. 300 mg once daily of a 50–55% bacoside-standardized extract — the dose used in nearly all positive RCTs (Stough et al. 2001, Roodenrys et al. 2002, Calabrese et al. 2008, Stough et al. 2008).
  2. Split dosing for GI tolerability. 150 mg twice daily with meals — same total dose, reported to produce a smoother GI experience for sensitive users.
  3. Higher dose (600 mg). 300 mg twice daily is used in some trials and tolerated, but without clear evidence of a larger cognitive effect.
  4. Branded-extract equivalence. For CDRI-08 and BacoMind, 320 mg/day is the manufacturer-recommended dose for both, matched to RCTs using those specific extracts.

Reported timeline: no measurable effect in the first 2–4 weeks; subtle improvements reported emerging at 5–6 weeks; the clinical-trial effect size reached at 8–12 weeks. For an acute focus or attention effect, Alpha-GPC, caffeine + L-theanine, or a racetam stack are the supplements typically discussed for same-day effects rather than Bacopa.

Label math. "500 mg Bacopa monnieri (50% bacosides)" is understood to mean 250 mg of actual bacoside content, within the RCT range. "500 mg Bacopa monnieri whole herb" with no bacoside percentage is unstandardized and may contain anywhere from 5–20% bacosides — a standardized extract with a stated bacoside percentage is the more verifiable choice.

How Bacopa monnieri is taken

Bacopa is taken orally, almost always as a capsule of standardized extract. Raw powder is available but bitter and inconsistently dosed; tinctures exist but offer no clear reported advantage.

AspectReported
FrequencyOnce daily (300 mg) or split twice daily (150 mg AM + 150 mg PM) — daily consistency is reported as more important than timing precision.
Best time of dayMorning or midday with a meal; evening dosing is also used and may have a mild calming effect for some users. Bacopa is not reported as stimulating.
FoodWith food — bacosides are lipophilic and absorption is reported to improve with dietary fat. An empty stomach is the most commonly reported cause of GI side effects.
FormStandardized extract capsule is preferred for a consistent bacoside dose; softgels with an oil base may improve absorption; raw powder is bitter and dose-imprecise; unstandardized whole-herb capsules do not disclose bacoside content.
Standardization markerA label reading "50–55% bacosides," or one of the branded clinical extracts (CDRI-08 or BacoMind), is the clearer standard. Unstandardized "whole herb" products do not disclose bacoside content.
CyclingNo cycling is reported as pharmacologically required — chronic daily use is the studied protocol. Some users cycle 8 weeks on / 2 weeks off to assess subjective benefit during washout.

What does Bacopa monnieri stack with?

Bacopa pairs naturally with faster-acting cognitive interventions because it operates on a different timescale. The acute supplements and peptides act quickly; Bacopa provides structural memory consolidation that builds over weeks. The three areas below cover the natural stacking categories.

With peptides

Bacopa is discussed alongside the Russian-origin cognitive peptide cluster. Semax (an ACTH(4-10) analog) is reported to modulate BDNF and neurotrophic signaling acutely — focus and resilience effects within minutes to hours. Selank (a tuftsin analog) is reported to provide anxiolytic and mild nootropic effects via GABA modulation, also acute. Bacopa is the slower, structural arm: dendritic branching, antioxidant neuroprotection, and acetylcholinesterase inhibition, with effects that build over 8–12 weeks. No known negative interaction is documented in the sources reviewed for this page; introducing one variable at a time is a common approach when starting a new combination.

With supplements

  1. Alpha-GPC — an acute acetylcholine substrate for daily attention, distinct from Bacopa's chronic memory-consolidation mechanism.
  2. Lion's Mane — NGF/BDNF stimulation on a similar weeks-to-months timescale, a different mechanism (neurotrophic) compatible with Bacopa's synaptic remodeling.
  3. Phosphatidylserine — cortisol-blunting plus membrane support, discussed as complementary to Bacopa's anxiolytic and neuroprotective arms.
  4. Rhodiola Rosea — adaptogenic stress modulation; both shift the stress response over chronic use, consistent with the Calabrese et al. 2008 anxiety findings.
  5. Caffeine + L-theanine — an acute focus stack discussed as compatible with Bacopa's chronic memory benefits, with no mechanistic conflict.

With lifestyle factors

  1. Daily consistency. The chronic-effect mechanism depends on regular daily use; anchoring to an existing daily habit is a common adherence strategy.
  2. Fat-containing meal. Bacosides are lipophilic — a meal with some fat is reported to improve bioavailability and reduce GI side effects.
  3. Time-boxed expectations. Evaluation at the 12-week mark rather than the 2-week mark is consistent with the trial timeline; discontinuing before the effect appears is a commonly reported reason Bacopa is perceived as ineffective.
  4. Learning windows. The Roodenrys et al. 2002 effect is specifically on retention of newly learned material, making Bacopa mechanistically well-matched to periods of intensive studying or training.

Side effects and interactions

Bacopa is reported as well-tolerated in published trials. The dominant cluster of side effects is gastrointestinal — nausea, cramping, loose stools — concentrated in users who take it on an empty stomach. Most other adverse effects reported are mild and dose-related.

Common (mostly transient)

  1. GI discomfort — nausea, cramping, loose stools or diarrhea, especially on an empty stomach; reported to resolve with food, dose reduction, or split dosing.
  2. Dry mouth — mild and inconsistent; reported in some users.
  3. Mild fatigue or sedation — particularly at higher doses (600 mg) or in sensitive users, discussed as reflecting Bacopa's mild anxiolytic/GABAergic component.
  4. Increased gastric motility — bacosides have mild cholinergic effects on smooth muscle.

Less common (watch-list)

  1. Bradycardia (slow heart rate) — Calabrese et al. 2008 documented a modest heart-rate reduction in the Bacopa group, clinically minor for most users but relevant for those with pre-existing bradycardia.
  2. Mild thyroid hormone elevation — animal data suggests Bacopa can raise T4; human relevance is unclear. A watch-list item for users on thyroid medication.
  3. Vivid dreams — occasionally reported, discussed as likely linked to serotonergic modulation.

Drug and supplement interactions

  1. Thyroid medications (levothyroxine, etc.) — Bacopa may modestly elevate T4 in animal models; clinician coordination is standard guidance for users on thyroid replacement.
  2. Anticholinergic medications (some antihistamines, tricyclic antidepressants, bladder medications) — Bacopa's acetylcholinesterase inhibition may partially oppose these drugs; clinician coordination is standard guidance for chronic anticholinergic therapy.
  3. Cholinesterase inhibitors (donepezil, rivastigmine) — an additive cholinergic effect is reported; clinician coordination is standard guidance.
  4. Sedatives (benzodiazepines, alcohol) — additive mild sedation is possible at higher Bacopa doses; not a contraindication but worth monitoring.
  5. Pregnancy and breastfeeding — data is insufficient; avoidance is standard guidance, since traditional Ayurvedic use does not constitute modern clinical safety evidence.

How should Bacopa monnieri be stored?

Bacosides are sensitive to heat, light, and humidity. Standardized extract capsules are reasonably stable in normal household storage, but active content is reported to degrade faster than in most supplements when exposed to heat or sunlight. Powdered Bacopa is more sensitive than encapsulated forms.

  1. Capsules and softgels: room temperature storage in the original sealed container, away from direct sunlight, is standard guidance. Use within 12 months of opening is common guidance. Bathroom and kitchen storage are generally avoided as the highest-heat-and-humidity rooms in most homes.
  2. Powder: an airtight opaque container immediately upon opening is standard guidance, since powdered Bacopa is more vulnerable to oxidation than the encapsulated form. Clear-jar storage on a sunny shelf is generally avoided.
  3. Storage above 25°C / 77°F for extended periods is generally discouraged, as bacoside content is reported to degrade faster at higher temperatures — a hot car or a kitchen near the oven represents a worst-case storage environment.
  4. Refrigeration is not required but is used in hot or humid climates; keeping the container sealed prevents condensation when warming to room temperature.
  5. Shelf life is typically reported as 18–24 months from manufacture when sealed, 12 months after opening. Checking the manufacture date at purchase is standard guidance, since Bacopa sitting on a warehouse shelf for 18+ months before purchase would be expected to have lower bacoside content than fresh stock.

What isn't established about Bacopa monnieri

Bacopa has one of the deeper traditional-herb RCT bases in the cognitive supplement literature, but several questions remain open, particularly around long-term safety in healthy populations, ADHD application validity, and the gap between the Indian and Western trial cohorts.

Long-term safety beyond 12 weeks. Nearly all RCT data is from 8–12 week trials. Multi-year daily use in healthy users is not characterized in controlled trials reviewed. Chronic daily 300 mg/day is generally regarded as safe based on tolerability and traditional use, but the long horizon is genuinely unstudied in modern RCT format.

Healthy young-adult cognitive transfer. Most positive cognitive evidence comes from older adults (Calabrese et al. 2008) or mixed middle-aged cohorts (Stough et al. 2001, Roodenrys et al. 2002). The case for healthy young adults wanting cognitive enhancement is mechanistically reasonable but less directly supported by trial data.

ADHD evidence base. A small set of Indian RCTs in pediatric ADHD shows promising results, but the evidence has not been replicated outside India and the methodology in some of these trials is weaker than Western standards.

Branded-extract vs commodity-extract equivalence. CDRI-08 and BacoMind have specific clinical-trial data; whether a generic 50% bacoside extract delivers equivalent outcomes is mechanistically plausible but not rigorously tested head-to-head.

Where studies disagree. The Kongkeaw et al. 2014 meta-analysis found moderate heterogeneity across trials. Working memory and acute attention effects are inconsistent, with some trials showing benefit and others showing null effects; the reliable signal is on delayed recall and consolidation.

Thyroid signal. Animal data suggests Bacopa can modestly elevate T4; clinical relevance in humans is unstudied. For most users this is not reported as an issue; for users on thyroid medication or with thyroid dysfunction, it is a watch-list item without clear guidance in the sources reviewed.

Product-quality considerations

Bacopa is available over-the-counter worldwide. Quality is reported to vary, particularly around bacoside standardization disclosure, the gap between "whole herb" and standardized-extract products, and the branded-vs-commodity-extract distinction.

Quality markers reported in the category

  • 50–55% bacoside standardization on the label — the RCT-matched concentration. Unstandardized "whole herb" products do not disclose this.
  • CDRI-08 or BacoMind branded extract — the two extracts with direct clinical-trial data, offering the closest match to the published RCTs.
  • Latin binomial on the label (Bacopa monnieri) — "Brahmi" alone can refer to a different herb (Centella asiatica) in some traditions.
  • Third-party tested — USP, NSF, or ConsumerLab certification signals independent verification.
  • Capsule form over raw powder (bitter, dose-imprecise) or undefined tinctures; softgels with an oil base may improve absorption.
  • No proprietary blends that obscure the actual Bacopa dose alongside other herbs or fillers.
  • Fresh manufacture date — bacosides degrade over time; a jar sitting on a warehouse shelf for more than 18 months pre-purchase is a quality concern.
Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

Bacopa monnieri FAQ

Why does Bacopa take 8–12 weeks to produce an effect?

Because the cognitive benefits are reported as structural, not acute. Bacosides A and B are reported to enhance dendritic branching and synaptic protein synthesis in hippocampal neurons — a slow remodeling process, not a fast neurotransmitter spike. Acute studies of a single Bacopa dose typically show no measurable cognitive effect; chronic studies at 8–12 weeks consistently show memory and processing-speed improvements. No effect in the first few weeks is expected under this model. For a same-day cognitive lift, Alpha-GPC, caffeine plus L-theanine, or a racetam stack are the supplements discussed for acute effects, not Bacopa.

What's the difference between CDRI-08, BacoMind, and generic 50% bacosides?

CDRI-08 is the originator standardized extract developed by India's Central Drug Research Institute, characterized at 55% bacosides via HPLC with a defined bacoside profile, and the extract used in several of the Stough and Roodenrys RCTs. BacoMind is a separately patented extract, also clinically studied, with a documented multi-bacoside profile (bacosides A1, A2, A3 and bacopasides). Generic "50% bacosides" is commodity-grade Bacopa standardized to total bacoside content but without the defined sub-fraction profile of the branded extracts. A reputable 50–55% bacoside extract is generally considered adequate; CDRI-08 or BacoMind is the extract most directly matched to the published RCTs.

Is long-term daily use supported, and is cycling necessary?

Long-term daily use is the model the published evidence supports — 12-week and longer trials report no concerning safety signals. There is no pharmacological rationale for cycling Bacopa the way a stimulant is cycled, since the mechanism is cumulative neural remodeling rather than receptor downregulation. Some users cycle 8 weeks on / 2 weeks off to assess subjective benefit, given that Bacopa's effects are subtle enough that a washout can help clarify whether it is still active. Discontinuation is reported to lead the cognitive benefits to fade over weeks, consistent with Bacopa functioning as a maintenance intervention rather than a one-shot one.

Why does Bacopa sometimes cause GI upset?

Bacopa is mildly cholinergic and can stimulate gastric motility — common side effects reported are nausea, cramping, and loose stools, especially when taken on an empty stomach. Taking Bacopa with food, ideally a meal containing some fat (bacosides are lipophilic and absorption is reported to improve with dietary fat), is the standard mitigation. If GI effects persist on a full stomach, a lower dose titrated up over 1–2 weeks is a common approach. Capsules are generally better tolerated than raw powder.

Is Brahmi the same as Bacopa monnieri?

Usually, but not always — this is a documented labeling ambiguity. In most modern usage, "Brahmi" refers to Bacopa monnieri. In some Ayurvedic traditions, however, "Brahmi" refers to Centella asiatica (gotu kola) — a different herb with different active compounds and effects. Reputable Bacopa products list both names ("Bacopa monnieri / Brahmi") and specify the bacoside standardization. A product labeled only "Brahmi" with no Latin name or bacoside percentage does not allow the buyer to confirm what is being purchased; the Latin binomial and a bacoside-percentage standardization are the relevant checks.

Does Bacopa stack with Semax or Selank?

The combination is discussed as mechanistically complementary, addressing different layers of cognitive function. Semax (an ACTH(4-10) analog) is reported to acutely modulate BDNF and neurotrophic signaling — fast-onset effects on focus and resilience. Selank (a tuftsin analog) is reported to provide anxiolytic and mild nootropic effects via GABA modulation — also acute. Bacopa is the chronic, structural arm: dendritic branching, antioxidant neuroprotection, and acetylcholinesterase inhibition, with effects that build over 8–12 weeks. No known negative interaction is documented in the sources reviewed for this page; introducing one variable at a time is a common approach to isolating each component's effect.

Does Bacopa work for anxiety or ADHD?

For anxiety, the evidence is reasonable: Calabrese et al. 2008 (an RCT in older adults) documented significant anxiety and depression reductions with chronic Bacopa supplementation. The mechanism is discussed as partly serotonergic and partly cortisol-modulating, producing an anxiolytic effect that builds gradually rather than acutely. For ADHD, the evidence is weaker: a 2014 Indian RCT in children with ADHD suggested cognitive and attention improvements with Bacopa, but the trial base is small, concentrated in one research group, and not replicated in Western populations — the ADHD application is best treated as plausible rather than established.

How does Bacopa compare to Alpha-GPC or Lion's Mane?

Different timescales and mechanisms, often used together. Alpha-GPC is an acetylcholine substrate — fast-acting, with reported daily attention and reaction-time effects, and evidence in dementia and acute exercise GH response. Lion's Mane is reported to work through NGF/BDNF stimulation — also chronic, on a weeks-to-months timescale, with evidence in mild cognitive impairment and nerve recovery. Bacopa is the memory-consolidation and anxiolytic arm — chronic, over 8–12 weeks, with evidence in healthy-adult memory and anxiety RCTs. The three mechanisms are distinct enough that combining them is mechanistically coherent.

References

  1. Stough C, Lloyd J, Clarke J, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology. 2001;156(4):481-484. Erratum: Psychopharmacology 2015;232(13):2427 (no PMID). https://pubmed.ncbi.nlm.nih.gov/11498727/
  2. Roodenrys S, Booth D, Bulzomi S, et al. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology. 2002;27(2):279-281. https://pubmed.ncbi.nlm.nih.gov/12093601/
  3. Calabrese C, Gregory WL, Leo M, et al. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008;14(6):707-713. https://pubmed.ncbi.nlm.nih.gov/18611150/
  4. Stough C, Downey LA, Lloyd J, et al. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res. 2008;22(12):1629-1634. https://pubmed.ncbi.nlm.nih.gov/18683852/
  5. Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528-535. https://pubmed.ncbi.nlm.nih.gov/24252493/
  6. Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J Altern Complement Med. 2010;16(7):753-759. https://pubmed.ncbi.nlm.nih.gov/20590480/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

Psychopharmacology · 2001Paywalled
Chronic Effects of an Extract of Bacopa monniera (Brahmi) on Cognitive Function in Healthy Human Subjects →

Stough C, Lloyd J, Clarke J, et al.

A 12-week randomized double-blind placebo-controlled trial of 300 mg/day Bacopa extract in 46 healthy adults. Reports Bacopa supplementation significantly improved speed of information processing, learning rate, and memory consolidation versus placebo. Cognitive gains emerged after the 5-week mark and were maximal at 12 weeks — establishing the chronic-effect timeline that subsequent Bacopa research has referenced. One of the foundational Western RCTs supporting Bacopa's clinical evidence base. Erratum: Psychopharmacology 2015;232(13):2427 (no PMID).

Neuropsychopharmacology · 2002Open Access
Chronic Effects of Brahmi (Bacopa monnieri) on Human Memory →

Roodenrys S, Booth D, Bulzomi S, et al.

A 12-week randomized double-blind placebo-controlled trial of Bacopa extract in 76 adults aged 40–65. Reports a significant effect on retention of new information, specifically reducing the rate of forgetting newly learned material on the Auditory Verbal Learning Test (AVLT). Working memory and short-term retrieval were not significantly affected. Establishes that Bacopa's memory benefit is specifically a consolidation/retention effect rather than a working-memory or acute-attention effect.

Journal of Alternative and Complementary Medicine · 2008Open Access
Effects of a Standardized Bacopa monnieri Extract on Cognitive Performance, Anxiety, and Depression in the Elderly: A Randomized, Double-Blind, Placebo-Controlled Trial →

Calabrese C, Gregory WL, Leo M, et al.

A 12-week RCT of 300 mg/day standardized Bacopa extract in 54 community-dwelling participants aged 65 and older. Reports Bacopa significantly improved AVLT delayed word recall and Stroop test performance, and reduced depression and anxiety scale scores versus placebo, with a modest decrease in heart rate in the Bacopa group. Extends Bacopa's evidence base into the older-adult population and provides combined cognitive and anxiolytic outcomes in a single trial.

Phytotherapy Research · 2008Paywalled
Examining the Nootropic Effects of a Special Extract of Bacopa monniera on Human Cognitive Functioning: 90 Day Double-Blind Placebo-Controlled Randomized Trial →

Stough C, Downey LA, Lloyd J, et al.

A 90-day RCT of 300 mg/day Bacopa extract in 62 healthy adults aged 18–60. Reports Bacopa significantly improved spatial working memory and rapid visual information processing, and reduced state anxiety versus placebo. The 90-day duration is consistent with the chronic-effect timeline reported across the Bacopa trial literature.

Journal of Ethnopharmacology · 2014Paywalled
Meta-Analysis of Randomized Controlled Trials on Cognitive Effects of Bacopa monnieri Extract →

Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, et al.

A systematic review and meta-analysis of nine double-blind placebo-controlled RCTs of Bacopa monnieri (n=437 total participants). Reports Bacopa significantly improved cognitive performance, particularly in tests of attention, cognitive processing, and choice reaction time; memory improvements were significant for delayed and free recall but inconsistent for working memory. Heterogeneity across trials was reported as moderate.

MemoryAyurvedicBacosidesCumulativeAnxiolytic8-12 Week Onset

Related Supplements

Alpha-GPCLion's ManePhosphatidylserineRhodiola RoseaCaffeine + L-Theanine

We may earn commissions from peptide vendor affiliate links.

Have a question about Bacopa Monnieri? Send us an email